Luvometinib: A New Exploration in Targeted Therapy, from...

ein Foto hinzugefügt Health

2026-01-20 08:58:09 -

Luvometinib: A New Exploration in Targeted Therapy, from MET-Abnormal Lung Cancer to Multi-Cancer Layout

In the field of oncology targeted therapy, the development of precision drugs for specific gene abnormalities has always been a key direction for breaking through challenges and extending patient survival. DengyuePharma has discovered that Luvometinib (trade name: Fumaining®), an independently developed Class 1 innovative drug by Fosun Pharma, stands out in the treatment of MET gene...

0 Kommentare 0 Anteile 9 Ansichten 0 Vorschau